Third-generation immucillins: Syntheses and bioactivities of acyclic immucillin inhibitors of human purine nucleoside phosphorylase

Journal of Medicinal Chemistry

Volumn 52, Issue 4, 2009, Pages 1126-1143

  Clinch, Keith ^a   Evans, Gary B ^a   Frohlich, Richard F G ^a   Furneaux, Richard H ^a   Kelly, Peter M ^a   Legentil, Laurent ^a   Murkin, Andrew S ^b   Li, Lei ^b   Schramm, Vern L ^b   Tyler, Peter C ^a   Woolhouse, Anthony D ^a  

^a CALLAGHAN INNOVATION   (New Zealand)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 7 [[(1,3 DIHYDROXYPROPAN 2 YL)AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 2 AMINO 7 [[[1,3,4 TRIHYDROXYBUTAN 2 YL]AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 3 [(4 HYDROXY 5H PYRROLO[3,2 D]PYRIMIDIN 7 YL)METHYLAMINO] PROPANOL; 7 [1 [(1,3 DIHYDROXYPROPAN 2 YL)AMINO] 2 HYDROXYETHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[(1,3 DIHYDROXYPROPAN 2 YL)(2 HYDROXYETHYL)AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[(1,3 DIHYDROXYPROPAN 2 YL)(METHYL)AMINO]METHYL]] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[(1,3 DIHYDROXYPROPAN 2 YL)AMINO]METHYL]] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[(2 HYDROXYETHYL)(3 HYDROXYPROPYL)AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[(2 HYDROXYETHYL)AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[(2,3 DIHYDROXYPROPYL)(2 HYDROXYETHYL)AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[(2,3 DIHYDROXYPROPYL)AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[(2,3,4 TRIHYDROXYBUTYL)AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[(2,3,4,5 TETRAHYDROXYPENTYL)AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[(2,4 DIHYDROXYBUTYL)METHYLAMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[(4 HYDROXYBUTYL)AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[[1,3 DIHYDROXY 2 (HYDROXYMETHYL)PROPAN 2 YL]AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[[1,3,4 TRIHYDROXYBUTAN 2 YL]AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[[3 HYDROXY 2 (HYDROXYMETHYL)PROPYL]AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[[3 HYDROXY 2 (HYDROXYMETHYL)PROPYLMETHYL]AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[[3,4 DIHYDROXY 2 (HYDROXYMETHYL)BUTYL]AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[BIS(2 HYDROXYETHYL)AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [[METHYL[ 1,3,4 TRIHYDROXYBUTAN 2 YL]AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; 7 [BENZYL[(2,3 DIHYDROXYPROPYL)AMINO]METHYL] 3,5 DIHYDRO 4H PYRROLO[3,2 D]PYRIMIDIN 4 ONE; ACYCLIC IMMUCILLIN INHIBITOR; FORODESINE; PURINE NUCLEOSIDE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

ADENINE; CATALYTIC DOMAIN; DRUG DESIGN; HUMANS; MOLECULAR CONFORMATION; PLIABILITY; PROTEIN BINDING; PURINE-NUCLEOSIDE PHOSPHORYLASE; PYRROLIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 64349107005     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801421q     Document Type: Article

References (49)

1. Taylor, E. A.; Clinch, K.; Kelly, P. M.; Li, L.; Evans, G. B.; Tyler, P. C.; Schramm, V. L. Acyclic ribooxacarbenium ion mimics as transition state analogues of human and malarial purine nucleoside phosphorylases. J. Am. Chem. Soc. 2007, 129, 6984-6985.
2. Rinaldo-Matthis, A.; Wing, C.; Ghanem, M.; Deng, H.; Wu, P.; Gupta, A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Almo, S. C.; Wang, C. C.; Schramm, V. L. Inhibition and structure of Trichomonas vaginalis purine nucleoside phosphorylase with picomolar transition state analogues. Biochemistry 2007, 46, 659-668.
3. Murkin, A. S.; Birck, M. R.; Rinaldo-Matthis, A.; Shi, W.; Taylor, E. A.; Almo, S. C.; Schramm, V. L. Neighboring group participation in the transition state of human purine nucleoside phosphorylase. Biochemistry 2007, 46, 5038-5049.
4. Taylor Ringia, E. A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Murkin, A. S.; Schramm, V. L. Transition state analogue discrimination by related purine nucleoside phosphorylases. J. Am. Chem. Soc. 2006, 128, 7126-7127.
5. Miles, R. W.; Tyler, P. C.; Furneaux, R. H.; Bagdassarian, C. K.; Schramm, V. L. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry. 1998, 37, 8615-8621.
6. Kicska, G. A.; Long, L.; Horig, H.; Fairchild, C.; Tyler, P. C.; Furneaux, R. H.; Schramm, V. L.; Kaufman, H. L. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phos- phorylase, selectively inhibits human T lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4593-4598.
7. Evans, G. B.; Furneaux, R. H.; Gainsford, G. J.; Schramm, V. L.; Tyler, P. C. Synthesis of Transition State Analogue Inhibitors for Purine Nucleoside Phosphorylase and N-Riboside Hydrolases. Tetrahedron 2000, 56, 3053-3062.
8. Evans, G. B.; Furneaux, R. H.; Lewandowicz, A.; Schramm, V. L.; Tyler, P. C. Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase. J. Med. Chem. 2003, 46, 3412-3423.
9. Lewandowicz, A.; Tyler, P. C.; Evans, G. B.; Furneaux, R. H.; Schramm, V. L. Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase. J. Biol. Chem. 2003, 278, 31465-31468.
10. Evans, G. B.; Furneaux, R. H.; Schramm, V. L.; Tyler, P. C. Synthesis of a transition state analogue inhibitor of purine nucleoside phospho- rylase via the Mannich reaction. Org. Lett. 2003, 5, 3639-3640.
11. Galmarini, C. M. Drug evaluation: forodesine-PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor. IDrugs 2006, 9,712-722.
12. Duvic, M. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. Oncology 2007, 21, 33-40.
13. Robak, T.; Lech-Maranda, E.; Koerycka, A.; Robak, E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr. Med. Chem. 2006, 13, 3165-3189.
14. Ravandi, F.; Gandhi, V. Novel purine nucleoside analogues for T-cell- lineage acute lymphoblastic leukaemia and lymphoma. Expert Opin. Investig. Drugs 2006, 15, 1601-1613.
15. Balakrishnan, K.; Nimmanpalli, R.; Ravandi, F.; Keating, M. J.; Gandhi, V. Forodesine, an inhibitor of purine nucleoside phosphory- lase, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2006, 108, 2392-2398.
16. Taylor Ringia, E. A.; Schramm, V. L. Transition states and inhibitors of the purine nucleoside phosphorylase family. Curr. Top. Med. Chem. 2005, 5, 1237-1258.
17. Giblett, E. R.; Ammann, A. J.; Wara, D. W.; Sandman, R.; Diamond, L. K. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1975, 1, 1010-1013.
18. Clinch, K.; Evans, G. B.; Fleet, G. W.; Furneaux, R. H.; Johnson, S. W.; Lenz, D. H.; Mee, S. P.; Rands, P. R.; Schramm, V. L.; Taylor Ringia, E. A.; Tyler, P. C. Syntheses and bio-activities of the L-enantiomers of two potent transition state analogue inhibitors of purine nucleoside phosphorylases. Org. Biomol. Chem. 2006, 4, 1131-1139.
19. Rinaldo-Matthis, A.; Murkin, A. S.; Ramagopal, U. A.; Clinch, K.; Mee, S. P. H.; Evans, G. B.; Tyler, P. C.; Furneaux, R. H.; Almo, S. C.; Schramm, V. L. L-Enantiomers of Transition State Analogue Inhibitors Bound to Human Purine Nucleoside Phosphorylase. J. Am. Chem. Soc. 2008, 130, 842-844.
20. Evans, G. B.; Furneaux, R. H.; Lewandowicz, A.; Schramm, V. L.; Tyler, P. C. Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase. J. Med. Chem. 2003, 46, 5271-5276.
21. Evans, G. B.; Furneaux, R. H.; Greatrex, B.; Murkin, A. S.; Schramm, V. L.; Tyler, P. C. Azetidine Based Transition State Analogue Inhibitors of N-Ribosyl Hydrolases and Phosphorylases. J. Med. Chem. 2008, 51, 948-956.
22. Chun, B. K.; Song, G. Y.; Chu, C. K. Stereocontrolled syntheses of carbocyclic C-nucleosides and related compounds. J. Org. Chem. 2001, 66, 4852-4858.
23. Semeraro, T.; Lossani, A.; Botta, M.; Ghiron, C.; Alvarez, R.; Manetti, F.; Mugnaini, C.; Valensin, S.; Focher, F.; Corelli, F. Simplified analogues of immucillin-G retain potent human purine nucleoside phosphorylase inhibitory activity. J. Med. Chem. 2006, 49, 6037-6045.
24. Elion, G. B.; Furman, P. A.; Fyfe, J. A.; de Miranda, P.; Beauchamp, L.; Schaeffer, J. Selectivity of action of an antiherpetic agent, 9-(2- hydroxyethoxymethyl)guanine. Proc. Natl. Acad. Sci. U.S.A. 1977, 74, 5716-5720.
25. Elion, G. B. Acyclovir: Discovery, Mechanism of Action and Selectivity. J. Virol. Med. Supp. 1993, 1, 2-6.
26. De Clercq, E. The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. Antiviral Res. 2007, 75, 1-13.
27. Khandazhinskaya, A.; Yasko, M.; Shirokova, E. The synthesis and antiviral properties of acyclic nucleoside analogues with a phospho- nomethoxy fragment in the side chain. Curr. Med. Chem. 2006, 13, 2953-2980.
28. Horton, D.; Thomas, S.; Gallucci, J. A synthetic route to 9-(polyhy- droxyalkyl)purines. Carbohydr. Res. 2006, 341, 2211-2218.
29. Lewandowicz, A.; Ringia, E. A.; Ting, L. M.; Kim, K.; Tyler, P. C.; Evans, G. B.; Zubkova, O. V.; Mee, S.; Painter, G. F.; Lenz, D. H.; Furneaux, R. H.; Schramm, V. L. Energetic mapping of transition state analogue interactions with human and Plasmodium falciparum purine nucleoside phosphorylases. J. Biol. Chem. 2005, 280, 30320-30328.
30. Schramm, V. L.; Tyler, P. C. Imino-sugar-based nucleosides. Curr. Top. Med. Chem. 2003, 3, 525-540.
31. Schramm, V. L. Enzymatic transition state theory and transition state analogue design. J. Biol. Chem. 2007, 282, 28297-28300.
32. Lewandowicz, A.; Schramm, V. L. Transition state analysis for human and Plasmodium falciparum purine nucleoside phosphorylases. Biochemistry 2004, 43, 1458-1468.
33. Schramm, V. L. Enzymatic transition states: thermodynamics, dynamics and analogue design. Arch. Biochem. Biophys. 2005, 433, 13-26.
34. Banphavichit, V.; Bhanthumnavin, W.; Vilaivan, T. Synthesis of new tridentate chiral aminoalcohols by a multicomponent reaction and their evaluation as ligands for catalytic asymmetric Strecker reaction. Tetrahedron 2007, 63, 8727-8734.
35. Chehade, K. A. H.; Baruch, A.; Verhelst, S. H. L.; Bogyo, M. An improved preparation of the activity-based probe JPM-OET and in situ applications. Synthesis 2005, 240-244.
36. Tang, Z.; Yang, Z.-H.; Chen, X.-H.; Cun, L.-F.; Mi, A.-Q.; Jiang, Y.-Z.; Gong, L.-Z. A highly efficient organocatalyst for direct aldol reactions of ketones with aldehydes. J. Am. Chem. Soc. 2005, 127, 9285-9289.
37. Breuning, A.; Vicik, R.; Schirmeister, T. An improved synthesis of aziridine-2,3-dicarboxylates via azido alcohols-epimerisation studies. Tetrahedron: Asymmetry 2003, 14, 3301-3312.
38. Soai, K.; Ookawa, A. Mixed Solvents Containing Methanol as Useful Reaction Media for Unique Chemoselective Reductions with Lithium Borohydride. J. Org. Chem. 1986, 51, 4000-4005.
39. Inaba, T.; Birchler, A. G.; Yamada, Y.; Sagawa, S.; Yokata, K.; Ando, K.; Uchida, I. A Practical Synthesis of Nelfinavir, an HIV-Protease Inhibitor, Using a Novel Chiral C4 Building Block: (5R,6S)-2,2-Dimethyl-5- hydroxy-1,3-dioxepan-6-ylammonium Acetate. J. Org. Chem. 1998, 63, 7582-7583.
40. Harnden, M. R.; Parkin, A.; Parratt, M. J.; Perkins, R. M. Novel Acyclonucleotides: Synthesis and Antiviral Activity of Alkenylphos- phonic Acid Derivatives of Purines and a Pyrimidine. J. Med. Chem. 1993, 36, 1343-1355.
41. Lemaire, M.; Posada, F.; Gourcy, J.-G.; Jeminet, G. Formal Synthesis of a 2- and 8-Functionalized 1,4,7-Trioxa-10-azaspiro[5.5]undecane. Synthesis 1995, 627-629.
42. 1 Receptor: Structure-Activity Relationships and Receptor Docking. J. Med. Chem. 2001, 44, 3092-3108.
43. Mitchell, D. L. Degradation of D-ribono-1→4-lactone to D-erythro- 1→4-lactone. Can. J. Chem. 1963, 41, 214-221.
44. Xu, B; Stephens, A.; Kirschenheuter, G; Greslin, A. F.; Cheng, X.; Sennelo, J.; Cattaneo, M.; Zighetti, M. L.; Chen, A.; Kim, S.-A.; Kim, H. S.; Bischofberger, N.; Cook, G.; Jacobson, K. A. Acyclic Analogues of Adenosine Bisphosphates as P2Y Receptor Antagonists: Phosphate Substitution Leads to Multiple Pathways of Inhibition of Platelet Aggregation. J. Med. Chem. 2002, 45, 5694-5709.
45. Janqueta, F.; Merchán, F. L.; Merino, P.; Tejero, T. A Straightforward Synthesis of L-isoserinal. Tetrahedron 1996, 52, 7045-7052.
46. Sanchez-Sancho, F.; Valverde, S.; Herradon, B. Stereoselective syntheses and reactions of chiral oxygenated α,β-unsaturated-γ- and (δ-lactones. Tetrahedron: Asymmetry 1996, 7, 3209-3246.
47. Dawson, R. M. C.; Elliott, D. C.; Elliott, W. H.; Jones, K. M. Data for Biochemical Research, 3rd ed.; Clarendon Press: Oxford, UK, 1986.
48. Lim, M.-I.; Ren, Y.-Y.; Otter, B. A.; Klein, R. S. Synthesis of "9- deazaguanosine" and other new pyrrolo[3,2-d]pyrimidine C-nucleo- sides. J. Org. Chem. 1983, 48, 780-788.
49. -1) due to a recent modification in the calculation algorithm; see also http://www.expasy.org/ tools/protparam.html